Manufacturing roundup: FDA, Swissmedic ink deal on pharma GMP; SK biotech contracts with Charles River for RNA therapy
The regulatory agencies of the US and Switzerland signed an agreement last week, allowing them to utilize each other’s good manufacturing practice (GMP) inspections of pharmaceutical manufacturing facilities — and bypass duplicate inspections.
This is the newest agreement that the FDA has with foreign entities, such as the EU and the UK. These agreements are thanks to a 2012 law that allowed the FDA to recognize inspections conducted by certain foreign regulators determined to be capable of inspections that met US requirements.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.